Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications

被引：5

作者：

Tamatam, Rekha ^{[1
]}

Mohammed, Arifullah ^{[1
]}

机构：

[1] Univ Malaysia Kelantan, Fac Agro Based Ind, Dept Agr Sci, Jeli 17600, Kelantan, Malaysia

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 272卷

关键词：

FDA; New drugs; Synthesis; Clinical applications; Oncology; Small molecules; CHRONIC MYELOID-LEUKEMIA; ENDOTHELIAL GROWTH-FACTOR; KINASE DOMAIN MUTATIONS; CELL LUNG-CANCER; SINGLE-ARM; PHASE-II; INHIBITOR; ABL; POTENT; FDA;

D O I：

10.1016/j.ejmech.2024.116441

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Drugs have structural homology across similar biological targets. Small molecule drugs have the efficacy to target specific molecular targets within the cancer cells with enhanced cell membrane permeability, oral administration, selectivity, and specific affinity. The objective of this review is to highlight the clinical importance and synthetic routes of new small molecule oncology drugs approved by the FDA during the period 2021-2022. These marketed drugs are listed based on the month and year of approval in chronological order. We believed that an in-depth insight into the synthetic approaches for the construction of these chemical entities would enhance the ability to develop new drugs more efficiently.

引用

页数：25

共 138 条

[21] The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity [J].

Canon, Jude ;

Rex, Karen ;

Saiki, Anne Y. ;

Mohr, Christopher ;

Cooke, Keegan ;

Bagal, Dhanashri ;

Gaida, Kevin ;

Holt, Tyler ;

Knutson, Charles G. ;

Koppada, Neelima ;

Lanman, Brian A. ;

Werner, Jonathan ;

Rapaport, Aaron S. ;

San Miguel, Tisha ;

Ortiz, Roberto ;

Osgood, Tao ;

Sun, Ji-Rong ;

Zhu, Xiaochun ;

McCarter, John D. ;

Volak, Laurie P. ;

Houk, Brett E. ;

Fakih, Marwan G. ;

O'Neil, Bert H. ;

Price, Timothy J. ;

Falchook, Gerald S. ;

Desai, Jayesh ;

Kuo, James ;

Govindan, Ramaswamy ;

Hong, David S. ;

Ouyang, Wenjun ;

Henary, Haby ;

Arvedson, Tara ;

Cee, Victor J. ;

Lipford, J. Russell .

NATURE, 2019, 575 (7781) :217-+

[22] Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor [J].

Caravella, Justin A. ;

Lin, Jian ;

Diebold, R. Bruce ;

Campbell, Ann-Marie ;

Ericsson, Anna ;

Gustafson, Gary ;

Wang, Zhongguo ;

Castro, Jennifer ;

Clarke, Andrea ;

Gotur, Deepali ;

Josephine, Helen R. ;

Katz, Marie ;

Kershaw, Mark ;

Yao, Lili ;

Toms, Angela, V ;

Barr, Kenneth J. ;

Dinsmore, Christopher J. ;

Walker, Duncan ;

Ashwell, Susan ;

Lu, Wei .

JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (04) :1612-1623

[23] Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].

Carter, TA ;

Wodicka, LM ;

Shah, NP ;

Velasco, AM ;

Fabian, MA ;

Treiber, DK ;

Milanov, ZV ;

Atteridge, CE ;

Biggs, WH ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Mehta, SA ;

Patel, HK ;

Pao, W ;

Sawyers, CL ;

Varmus, H ;

Zarrinkar, PP ;

Lockhart, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016

[24] Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors [J].

Cortes, Jorge ;

Jabbour, Elias ;

Kantarjian, Hagop ;

Yin, C. Cameron ;

Shan, Jianqin ;

O'Brien, Susan ;

Garcia-Manero, Guillermo ;

Giles, Francis ;

Breeden, Megan ;

Reeves, Nubia ;

Wierda, William G. ;

Jones, Dan .

BLOOD, 2007, 110 (12) :4005-4011

[25] Development of a Safe Process for Manufacturing of the Potent Anticancer Agent Melflufen Hydrochloride [J].

Cotton, Hanna ;

Backstrom, Birthe ;

Fritzson, Ingela ;

Lehmann, Fredrik ;

Monemi, Taraneh ;

Oltner, Viveca ;

Solver, Ellen ;

Wahlstrom, Niklas ;

Wennerberg, Johan .

ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (06) :1191-1196

[26] IDH mutations in glioma and acute myeloid leukemia [J].

Dang, Lenny ;

Jin, Shengfang ;

Su, Shinsan M. .

TRENDS IN MOLECULAR MEDICINE, 2010, 16 (09) :387-397

[27] Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial [J].

Daniel, Davey ;

Kuchava, Vladimer ;

Bondarenko, Igor ;

Ivashchuk, Oleksandr ;

Reddy, Sreekanth ;

Jaal, Jana ;

Kudaba, Iveta ;

Hart, Lowell ;

Matitashvili, Amiran ;

Pritchett, Yili ;

Morris, Shannon R. ;

Sorrentino, Jessica A. ;

Antal, Joyce M. ;

Goldschmidt, Jerome .

INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (10) :2557-2570

[28] Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study [J].

Davids, Matthew S. ;

Kim, Haesook T. ;

Nicotra, Alyssa ;

Savell, Alexandra ;

Francoeur, Karen ;

Hellman, Jeffrey M. ;

Bazemore, Josie ;

Miskin, Hari P. ;

Sportelli, Peter ;

Stampleman, Laura ;

Maegawa, Rodrigo ;

Rueter, Jens ;

Boruchov, Adam M. ;

Arnason, Jon E. ;

Jacobson, Caron A. ;

Jacobsen, Eric D. ;

Fisher, David C. ;

Brown, Jennifer R. .

LANCET HAEMATOLOGY, 2019, 6 (01) :E38-E47

[29] Clinical efficiency of epigenetic drugs therapy in bone malignancies [J].

de Nigris, Filomena ;

Ruosi, Carlo ;

Napoli, Claudio .

BONE, 2021, 143

[30] Asciminib: First Approval [J].

Deeks, Emma D. .

DRUGS, 2022, 82 (02) :219-226

← 1 2 3 4 5 6 7 8 9 10 →